Pulmonary oxygen uptake and muscle deoxygenation kinetics during heavy intensity cycling exercise in patients with emphysema and idiopathic pulmonary fibrosis

Melitta A. McNarry1*, Nicholas K. Harrison2,3, Tom Withers1, Narendra Chinnappa3 and Michael J. Lewis1

Abstract

Background: Little is known about the mechanistic basis for the exercise intolerance characteristic of patients with respiratory disease; a lack of clearly defined, distinct patient groups limits interpretation of many studies. The purpose of this pilot study was to investigate the pulmonary oxygen uptake ($$\dot{V}$$O2) response, and its potential determinants, in patients with emphysema and idiopathic pulmonary fibrosis (IPF).

Methods: Following a ramp incremental test for the determination of peak $$\dot{V}$$O2 and the gas exchange threshold, six emphysema (66 ± 7 years; FEV1, 36 ± 16%), five IPF (65 ± 12 years; FEV1, 82 ± 11%) and ten healthy control participants (63 ± 6 years) completed three repeat, heavy-intensity exercise transitions on a cycle ergometer. Throughout each transition, pulmonary gas exchange, heart rate and muscle deoxygenation ([HHb], patients only) were assessed continuously and subsequently modelled using a mono-exponential with ($$\dot{V}$$O2, [HHb]) or without (HR) a time delay.

Results: The $$\dot{V}$$O2 phase II time-constant ($$\tau$$) did not differ between IPF and emphysema, with both groups significantly slower than healthy controls (Emphysema, 65 ± 11; IPF, 69 ± 7; Control, 31 ± 7 s; P < 0.05). The HR $$\tau$$ was slower in emphysema relative to IPF, with both groups significantly slower than controls (Emphysema, 87 ± 19; IPF, 119 ± 20; Control, 58 ± 11 s; P < 0.05). In contrast, neither the [HHb] $$\tau$$ nor [HHb]:O2 ratio differed between patient groups.

Conclusions: The slower $$\dot{V}$$O2 kinetics in emphysema and IPF may reflect poorer matching of O2 delivery-to-utilisation. Our findings extend our understanding of the exercise dysfunction in patients with respiratory disease and may help to inform the development of appropriately targeted rehabilitation strategies.

Keywords: Respiratory disease, $$\dot{V}$$O2 kinetics, NIRS, Cycle

Background

Pulmonary oxygen uptake ($$\dot{V}$$O2) kinetics provides an insight into the integrated capacity of an organism to transport and utilize oxygen to support an increased rate of energy turnover in contracting myocytes [1]. This dynamic $$\dot{V}$$O2 response is highly sensitive to both advantageous and deleterious adaptations. For example, the $$\dot{V}$$O2 kinetics of patients with chronic obstructive pulmonary disease (COPD) are slower than their age-matched controls [e.g. 2–4] but this can be ameliorated, to some extent, by exercise training [3, 5]. This slow $$\dot{V}$$O2 kinetic response has been suggested to be mechanistically associated with the reduced exercise tolerance typical of this population [6–10].

The pathological basis for the slower dynamic $$\dot{V}$$O2 response in COPD remains uncertain, with little consensus within the literature regarding the principal determinants of the slower $$\dot{V}$$O2 kinetics observed during moderate intensity exercise. Skeletal muscle dysfunction characterized by a decreased capillary network [11],...
reduced myoglobin level [12], abnormal oxidative capacity [13, 14] and altered muscle fibre type distribution (increased relative proportion of type II, glycolytic muscle fibres [7]) have been suggested to be associated with the slower $\dot{V}$ \textsubscript{O2} kinetics [2, 15] and positive responses to training reported in some previous studies [5, 8]. However, others have suggested that the cardiovascular derangements often present in those with COPD may engender an oxygen delivery limitation leading to the slower dynamic $\dot{V}$ \textsubscript{O2} response observed [3, 16], a contention supported by the limited evidence available regarding the $\dot{V}$ \textsubscript{O2} response during heavy intensity exercise [4]. Further interpretation of these findings is limited, however, by methodological limitations such as the reliance on a single exercise bout for the derivation of $\dot{V}$ \textsubscript{O2} kinetics, which may not reflect the true response [17], and significant potential variability in patient populations. Specifically, COPD is an umbrella term that encompasses different pathological entities including chronic bronchitis, emphysema, small airways disease and respiratory bronchiolitis interstitial lung disease [18]. Some or all of these entities may be present within an individual in varying proportion.

In contrast to emphysema, there is a paucity of data on exercise response of patients with fibrotic lung disease [19]. Idiopathic pulmonary fibrosis (IPF) is a common life-limiting condition characterized by progressive deposition of extracellular matrix in the alveolar interstitium. This condition is thought to arise from aberrant wound healing following alveolar epithelial injury [20]. IPF results in symptoms of increasing breathlessness, functional decline and eventual death, with a median survival time of approximately three years following diagnosis [21].

While emphysema and IPF are distinct pathological conditions, both result in a loss of functional alveolar units and impaired gas exchange. However, the destructive process of emphysema causes a loss of elastic recoil in the lungs, resulting in gas trapping and airflow obstruction on expiration with a relative fall in forced expiratory volume (FEV\textsubscript{1}) compared to forced vital capacity (FVC). In contrast, increased extracellular matrix in the alveolar walls of patients with IPF causes the lungs to fibrose with a consequent reduction in lung volumes and a matched fall in FEV\textsubscript{1} and FVC. Therefore, the vital capacity of patients with IPF becomes progressively decreased without affecting airflow [20]. The differential manifestation of these pathological adaptations with regards to the $\dot{V}$ \textsubscript{O2} kinetics response is presently unknown, although it is perhaps pertinent to note the central role of arterial desaturation in exercise intolerance reported in patients with IPF [22, 23].

In this context, the purpose of the present pilot study was to investigate the $\dot{V}$ \textsubscript{O2} kinetics response, during heavy intensity exercise in well-characterized patients with emphysema and IPF.

**Methods**

**Participants**

Overall, eleven patients and ten healthy volunteers (62.8 ± 6.4 years; 9 males) who served as a control group completed this study (Table 1). The patient group comprised of six patients with emphysema (66.4 ± 7.4 years; 5 male; GOLD classification stage II, n = 1; stage III, n = 3 and stage IV, n = 2) and five patients with IPF (64.7 ± 11.6 years; 4 males). One patient with emphysema and two with IPF dropped out due to issues unrelated to the study. Furthermore, one patient with Emphysema was excluded from the subsequent analyses due to concern regarding the quality of the data and the values derived.

None of the patients in either group were current smokers and none had clinical evidence of pulmonary hypertension. No patient had suffered from a respiratory infection or an acute exacerbation of their condition over the six months prior to the study. None of the patients had been prescribed oral corticosteroids or antibiotics during this time.

Inclusion criteria for patients with emphysema were: a history of cigarette smoking, FEV\textsubscript{1}/FVC ratio <0.7, and resting arterial PO\textsubscript{2} > 60 Torr in room air. In addition, all emphysema patients had radiographic/CT evidence of hyperinflation and destruction of lung parenchyma typical of emphysema. All six patients were taking 18 μg of inhaled tiotropium daily and five patients were also taking an inhaled corticosteroid/long acting beta-2 agonist combination, comprising 500 μg of fluticasone and 50 μg of salmeterol twice daily.

**Table 1** Anthropometric characteristics and lung function according to participant condition

|            | Healthy | Emphysema | IPF |
|------------|---------|-----------|-----|
| Age (yrs)  | 62.8 ± 6.4 | 66.4 ± 7.4 | 64.7 ± 11.6 |
| Stature (m) | 1.74 ± 0.11 | 1.67 ± 0.14 | 1.71 ± 0.07 |
| Body Mass (kg) | 76.3 ± 13.9 | 68.4 ± 8.9 | 79.0 ± 16.3 |
| BMI (kg · m\textsuperscript{-2}) | 25.1 ± 3.3 | 24.6 ± 2.8 | 26.7 ± 3.5 |
| BF (%) | 26 ± 6 | 27 ± 9 | 28 ± 5 |
| FEV\textsubscript{1} (%) | - | 51 ± 25 | 89 ± 11\textsuperscript{a} |
| FVC (%) | - | 94 ± 27 | 97 ± 24 |
| FEV\textsubscript{1}/FVC | - | 50 ± 14 | 97 ± 16\textsuperscript{a} |
| DL\textsubscript{co} (%) | - | 46 ± 17 | 47 ± 17 |
| Kco (%) | - | 55 ± 10 | 65 ± 25 |

Mean ± SD. BMI: body mass index; BF: body fat; FEV\textsubscript{1}: Forcend Expiratory Volume in one second; FVC: Forced Vital Capacity; DL\textsubscript{co}: carbon monoxide transfer coefficient; Kco: carbon monoxide transfer coefficient. All parameters of lung function are expressed as mean percent predicted for age and height [64, 65]. *Significant difference between Emphysema and IPF
All patients with IPF fulfilled the 2011 American Thoracic Society/European Respiratory Society criteria for this diagnosis. In particular, all IPF patients had clinical, radiological and physiological features consistent with a diagnosis of IPF. Each patient had undergone high resolution computed tomography (HRCT) to confirm the presence of pulmonary fibrosis, with predominant reticular or honeycomb pattern in the subpleural regions of the lung bases and little or no ground glass shadowing. One patient had undergone a surgical lung biopsy, which showed the histological pattern of usual interstitial pneumonia.

The control group comprised healthy volunteers who were non-smokers. All were physically active but none were involved in organized sports.

All participants in the study gave written, informed consent and the study protocol was approved by the local NHS Ethics Committee (Ref number: 102547), which adhered to the Declaration of Helsinki.

**Procedures**

The participants were asked to arrive at the laboratory in a rested state, ~2 h postprandial and to avoid strenuous exercise in the 24 h preceding each testing session. The participants also refrained from taking caffeine for 6 h and alcohol for 24 h before each test, respectively. All the tests were performed at the same time of day (±2 h) and exercise testing was conducted using an electronically braked cycle ergometer (Lode Excalibur, Groningen, Netherlands).

**Incremental Test**

The incremental exercise test began with 3 min cycling at 70 – 80 rpm against no additional resistance, followed by increments of 6–10 W · min⁻¹ and 20–30 W · min⁻¹ for patients and controls, respectively, until exhaustion. These ramp rates were chosen on the basis of each participant’s self-reported history of physical activity and symptoms and are in accord with those utilized in Chiappa et al. [4] in patients with COPD. The participants were asked to maintain a cadence of 70–80 rpm. Breath-by-breath pulmonary gas-exchange data were collected continuously during the incremental exercise tests (Jaeger, Oxycon Pro, Carefusion, San Diego). The highest average $\dot{V}\text{O}_2$ measured over 10 s before exhaustion was taken as the peak $\dot{V}\text{O}_2$ ($\dot{V}\text{O}_2$ peak). The gas exchange threshold (GET) was determined as the $\dot{V}\text{O}_2$ at which there was 1) a non-linear increase in carbon dioxide production (VCO₂) relative to $\dot{V}\text{O}_2$ and 2) an increase in minute ventilation (VE)/ $\dot{V}\text{O}_2$ without an increase in VE/VCO₂.

**Step Exercise Tests**

For the determination of $\dot{V}\text{O}_2$, heart rate (HR) and deoxyhemoglobin ([HHb]) kinetics, participants completed a series of “step” tests. The protocol, which was performed three times on separate days a minimum of 24 h apart, comprised 6 min of pedaling with no external resistance followed by an abrupt transition to the target heavy intensity work rate which was maintained for a further 6 mins. The heavy intensity work rate was calculated as the work rate that would elicit a $\dot{V}\text{O}_2$ of 40% of the difference between the GET and peak $\dot{V}\text{O}_2$ (Δ40%). Following the observation of the low mean work rate associated with Δ40% in this population (37 ± 12 w), no external resistance was added to the baseline period to prevent further reductions in the already small response amplitude. According to the manufacturer guidelines, “unloaded” pedaling is equivalent to 10w at 70 rpm. Throughout each exercise bout, participants maintained a cadence of 70–80 rpm.

**Measurements**

During the exercise tests, the participants wore a face-mask and breathed through an impeller turbine assembly (Jaeger Triple V, Hoechberg, Germany). The inspired and expired gas volumes and gas concentration signals were continuously sampled at 100 Hz. These analyzers were calibrated before each test with gases of known concentrations, and the turbine volume transducer was calibrated using a 3 l syringe (Hans Rudolph, Kansas City, MO). The volume and concentration signals were time-aligned by accounting for the delay in capillary gas transit and analyzer rise-time relative to the volume signal. HR was measured throughout the exercise tests using a three lead echocardiogram (ECG; Reynolds LifeCard CF digital Holter recorder, Spacelabs Healthcare Ltd., UK). The ECG leads were positioned in the modified V5, CC5, modified V5R electrode configuration. This system provided ECG data with a sample accuracy of 2.5 mV (magnitude of least significant bit; 12-bit resolution) and 1024 Hz sampling frequency.

Additionally, the oxygenation status of the right m. vastus lateralis was monitored during each transition using a commercially available near-infrared system (Portamon, Artinis Medical Systems, The Netherlands). This system consists of an emission probe which has three light sources and emits two wavelengths of light (760 and 850 nm) and a photon detector. The intensity of incident and transmitted light was recorded continuously at 10 Hz and used to estimate the concentration changes relative to zero-set baseline levels for oxygenated, deoxygenated, and total hemoglobin. The [HHb] was used as an indicator of oxygen extraction within the field of interrogation [e.g. 24, 25]. The contribution of myoglobin to the NIRS signal is currently unresolved and so the [HHb] signal described herein should be considered to refer to the combined concentration of both deoxygenated hemoglobin and myoglobin. Given recent evidence regarding the issues of proportionality between
the $\dot{V}\cdot O_2$ and [HHb] response to step exercise, the absolute amplitude changes were not considered [26]. The muscle was initially cleaned and the portable probe strapped to the skin at the midpoint of the muscle using physiotherapists’ tape (Kinesio Tex Gold). To ensure the device remained stationary during exercise, and to minimize the interference of extraneous light with the near-infrared signal, a bandage was wrapped around the leg to enclose the probe.

$\dot{V}\cdot O_2$ kinetics analysis
Initially, the breath-by-breath $\dot{V}\cdot O_2$ responses to each step transition were visually examined to remove any errant breaths caused by coughing, swallowing, sighing etc., using a 5-s moving average to identify points lying in excess of four standard deviations from the mean. Subsequently, each transition was interpolated to 1-s intervals, time aligned to the start of exercise and averaged to produce a single response profile. Following baseline correction, a mono-exponential model with a time delay (Eq. 1) was then applied to this averaged response:

$$\dot{V}O_2(t) = A_1 \cdot \left(1 - e^{-\left(t-\delta_1\right)/\tau_1}\right)$$  \hspace{1cm} (1)

where $\dot{V}\cdot O_2$ is the increase in $\dot{V}\cdot O_2$ at time $t$ above the baseline value (calculated as the mean $\dot{V}\cdot O_2$ from the first 45 s of the last minute of baseline pedaling), and $A_1$, $\delta_1$ and $\tau_1$ are the primary component amplitude, time delay (which was allowed to vary freely), and time constant, respectively. Kinetic variables ($A_1$, $\delta_1$ and $\tau_1$) and their 95% confidence intervals were determined by least squares non-linear regression analysis (Graphpad Prism, Graphpad Software, San Diego, CA). In accord with previous studies [27–29], a mono-exponential model was used because a bi-exponential model ($\Delta\dot{V}O_2(t) = A_1 \cdot \left(1 - e^{-\left(t-\delta_1\right)/\tau_1}\right) + A_2 \cdot \left(1 - e^{-\left(t-\delta_2\right)/\tau_2}\right)$) was found to produce an inferior and ambiguous fit. Indeed, given that the purpose of the bi-exponential model is, at least in part, to identify and characterize the slow component, this failure to accurately fit the data is likely attributable to the negligible slow component evident in our participants, as verified by methods previously described elsewhere [30]. Briefly, purpose-designed LabVIEW software was used which iteratively fitted a single exponential function to the $\dot{V}\cdot O_2$ data until the window encompassed the entire exercise response. The resulting phase II time constants were plotted against time to identify the point at which the phase II time constant consistently deviated from the previously “flat” profile. The amplitude of the $\dot{V}\cdot O_2$ slow component was subsequently determined by calculating the difference between the end exercise $\dot{V}\cdot O_2$ and the sum of the primary amplitude and baseline $\dot{V}\cdot O_2$. This was expressed both in absolute terms and relative to end-exercise $\dot{V}\cdot O_2$. Finally, the mean response time (MRT), which reflects the time course of the entire $\dot{V}\cdot O_2$ response, was calculated by fitting a single exponential curve with no time delay to all data from $t = 0$.

[HHb] & HR Kinetics Analysis
The [HHb] and HR responses to exercise were also modelled. The responses to each transition were interpolated to 1-s intervals, time-aligned and averaged to produce a single data set. The time delay for the [HHb] response ([HHb] TD) was identified as the time after exercise onset at which [HHb] began a systematic increase above the nadir value. The [HHb] data were subsequently fitted with a single exponential with a time delay (Eq. 1); the fitting window started at the [HHb] TD and finished at the end of the exercise transition. In accord with previous studies [e.g. 29, 31–33], the HR response was modelled by a mono-exponential without a time delay (Eq. 2) with the fitting window started at $t = 0$.

$$\Delta HR(t) = A_1 \cdot \left(1 - e^{-\left(t-\tau_1\right)/\tau_1}\right)$$  \hspace{1cm} (2)

where $\Delta HR$ is the increase in heart rate at time $t$ above the baseline (calculated as the mean heart rate from the first 45 s of the last minute of baseline pedaling), and $A_1$ and $\tau_1$ are the primary component amplitude and time constant, respectively. The [HHb] time delay and $\tau$ were summed, giving the effective [HHb] $\tau^*$ that reflects the overall time course of the [HHb] response from the onset of the step transition. The [HHb]/$\dot{V}\cdot O_2$ ratio was also calculated to provide a general index of the “excess” (relative to the steady-state values) $O_2$ extraction for a given $\dot{V}\cdot O_2$ [34]. Specifically, values $>1.0$ reflect a greater reliance on fractional $O_2$ extraction compared with the exercise steady-state (values $=1.0$) and reflects a poorer local $O_2$ delivery relative to muscle $O_2$ utilization in the area of interrogation. The second-by-second [HHb] and $\dot{V}\cdot O_2$ data were normalised for each participant and the $\dot{V}\cdot O_2$ left-shifted by 20s to account for the cardiodynamic phase, synchronizing the datasets for exercise onset. Subsequently, both data sets were averaged into 5 s time bins and the ratio of [HHb]: $\dot{V}\cdot O_2$ was calculated for each time bin from 20 s to the end of exercise. The average of all the individual time bins was calculated to produce an overall “mean” ratio.

Statistics
Between groups differences (healthy, emphysema or IPF) were assessed using an ANOVA with subsequent post-hoc comparisons using Tukey’s test where appropriate to identify the location of significant differences. Pearson’s product moment correlation coefficients were used to analyze the relationships between key variables. All statistical analyses were conducted using PASW Statistics 18 (SPSS,
Chicago, IL). All data are presented as means ± SD. Statistical significance was accepted when _P_ ≤ 0.05.

**Results**

**Peak Exercise**

Participant’s peak exercise values are shown in Table 2. Both patient groups demonstrated a significantly lower peak _V̇_O₂ than their healthy counterparts in absolute and relative terms. Emphysema patients had lower absolute peak _V̇_O₂ than IPF patients, but this difference was eliminated when expressed relative to fat free mass. The absolute GET was significantly higher in the healthy participants with no difference evident between emphysema and IPF patients. When the GET was expressed relative to peak _V̇_O₂, there were no differences between participant groups. There were no differences between emphysema and IPF patients in peak tidal volume (_V̇_T₁), breathing frequency or minute ventilation (_V̇_E). IPF demonstrated significantly lower values than healthy participants for both _V̇_T (1.71 ± 0.63 vs. 3.08 ± 0.78 l·min⁻¹, respectively; _P_ = 0.018) and _V̇_E (59.2 ± 31.2 vs. 101.4 ± 29.2 l·min⁻¹, respectively; _P_ = 0.042), while _V̇_E was significantly lower in emphysema than healthy participants (32.0 ± 13.7 vs. 101.4 ± 29.2 l·min⁻¹, respectively; _P_ = 0.001).

**Constant work rate exercise**

As summarized in Table 3 and illustrated in Fig. 1, the dynamic _V̇_O₂ response was significantly influenced by both lung diseases. Specifically, whilst emphysema and IPF patients did not differ from each other, both showed a significantly lower phase II amplitude and relative slow component amplitude and slower phase II _τ_ and MRT compared to healthy participants. In contrast, in addition to being slower than healthy participants, emphysema patients evidenced a significantly slower HR response following the onset of exercise. Emphysema and IPF patients demonstrated a similar [HHb] _τ_ and effective [HHb] _τ_. The overall [HHb]: _V̇_O₂ ratio did not differ significantly between IPF and emphysema patients. Irrespective of patient group, there was a transient overshoot in the [HHb]: _V̇_O₂ response following the step change in exercise demand (Fig. 2).

There were no significant differences in steady state _V̇_T (1.85 ± 0.56, 1.59 ± 0.48, 2.21 ± 0.57 l·min⁻¹), breathing frequency (32.8 ± 6.9, 38.3 ± 6.2, 39.3 ± 4.3 breathes) or _V̇_E (46.7 ± 35.7, 44.0 ± 12.8, 38.1 ± 3.3 l·min⁻¹) between emphysema, IPF and healthy participants, respectively.

A significant relationship was present between peak _V̇_O₂ and the _V̇_O₂ _τ_ (r = -0.80; _P_ = 0.000), _V̇_O₂ MRT (r = -0.73; _P_ = 0.000), relative slow component percentage (r = 0.63; _P_ = 0.008) and HR _τ_ (r = -0.85; _P_ = 0.000). Furthermore, the _V̇_O₂ _τ_ and HR _τ_ were significantly related (r = 0.81; _P_ = 0.000). There was no relationship between the _V̇_O₂ _τ_ and the [HHb]/ _V̇_O₂ ratio.

**Discussion**

This is the first study to explore the influence of emphysema and IPF on the dynamic adjustments of pulmonary _V̇_O₂, HR and localized muscle fractional oxygen extraction during heavy intensity cycling exercise. We found that both patient groups had impaired exercise responses with slower _V̇_O₂ and HR kinetics relative to their healthy counterparts. Interestingly and contrary to our experimental hypothesis, the _V̇_O₂ and [HHb] response profiles in emphysema and IPF were similar, although the former demonstrated a significantly slower HR response. These findings suggest that, whilst emphysema and IPF have quite different clinical and histopathological features,
exercise rehabilitation programs may wish to target the enhancement of systemic \( \dot{V}_{\text{O}_2} \) delivery and peripheral muscle \( \text{O}_2 \) availability to minimize the functional aerobic fitness impairments typical of people suffering from both conditions.

The slower pulmonary \( \dot{V}_{\text{O}_2} \) kinetics in our patients with emphysema are in accord with those previously reported in COPD patients during both moderate [3, 5] and heavy intensity exercise [4]. The present study is novel in that we utilised multiple (rather than single) heavy intensity exercise transitions and recruited only those patients with clearly defined emphysema. Consequently, our resulting confidence intervals for \( \tau \) in the dynamic responses of \( \dot{V}_{\text{O}_2} \) (5 ± 2 s), HR (5 ± 3 s) and [HHb] (2 ± 1 s) are commensurate with those recommended by Fawkner and Armstrong [35], although it is pertinent to note the potential influence of our chosen interpolation techniques on these confidence intervals [36, 37]. Indeed, while three exercise transitions have been shown be associated with the lowest confidence intervals [at least compared to 1, 2, 4 or 6 transitions; 38], the applicability of such findings to the small amplitudes reported in the present study is likely to be limited [39].

The factors that determine the \( \dot{V}_{\text{O}_2} \) response are still contentious, yet will be fundamental to the future development of effective pulmonary rehabilitation exercise programs for people with respiratory disease. Previous studies of moderate and heavy intensity exercise have suggested that oxygen delivery may represent the primary rate-limiting factor of the \( \dot{V}_{\text{O}_2} \) kinetics in COPD [3, 4, 16]. This assertion is largely based on observations of impaired HR kinetics, which are thought to provide a good proxy of the kinetics of cardiac output and muscle blood flow [40, 41]. However, Chiappa et al. [4] have suggested that focusing on the dynamic HR may be inappropriate as they attributed the slower kinetics of cardiac output in their patients predominantly to a slower increase in stroke volume (52% slower \( \tau \)) rather than heart rate (40% slower \( \tau \)). Our observation that patients with emphysema had a 70% slower HR kinetic response compared to healthy controls implies a considerable limitation in central oxygen delivery following the onset of exercise. This notion is further supported by the
[HbO2]: VO2 ratio which demonstrated an overshoot in both patient groups at the onset of exercise, with mean values >1.0 across the exercise transition. This is indicative of a mismatch between microvascular O2 distribution and muscle O2 utilisation in the active tissues, requiring a greater reliance on O2 extraction for a given relative VO2 [26, 34]. The values reported in the present study, at least for the IPF patients, are similar to those recently reported in untrained older adults [42]. It is interesting to note the considerably lower values in the emphysema patients, although we accept this may be a methodological artefact due to the small sample size and low signal-to-noise ratio.

Recent findings in healthy older adults suggest that impairments in the dynamics of O2 delivery may be related to the slowing of VO2 kinetics generally observed with ageing [43–46]. Given that COPD and IPF typically present in older adults, it is feasible that the pathological derangements associated with these diseases may engender further impairments in the dynamics of O2 delivery and, thus, the VO2 kinetic response. Certainly, multiple perturbations, such as an altered autonomic balance [47] and altered mechanics and muscle fibre recruitment patterns of breathing [6, 48, 49], have been identified in people with COPD and could contribute to an O2 delivery limitation. Furthermore, people with COPD are known to have an increased cardiac sympathetic tone [30] and at the onset of exercise, cardiac parasympathetic withdrawal may be less pronounced compared to their healthy counterparts. Given that sympathetic activation is considerably slower at increasing heart rate than parasympathetic withdrawal [50], this autonomic imbalance could explain the slower HR response at the onset of exercise. Expiratory flow limitations can result in higher intrathoracic pressures during expiration in those with COPD which could impair right ventricular filling and left ventricular ejection [6] and hence further reduce O2 delivery. Indeed, simulated expiratory flow limitations in healthy adults caused significantly slower recovery VO2 kinetics [51]. These negative cardio-circulatory consequences may additionally, or alternatively, be elicited through the significant contribution of the abdominal muscles to breathing in some patients with COPD which similarly increases expiratory pressure [48]. Finally, the increased work of breathing in those with COPD [6], especially during exercise, may divert a greater proportion of blood flow to the respiratory muscles, potentially decreasing blood flow and thus O2 delivery to the exercising muscles [52].

The slower dynamic VO2 response in patients with emphysema may also be caused by factors independent of cardiac output. For example, increased sympathetic tone may result in vasoconstriction, impairing muscle blood flow and thus reducing O2 delivery [53]. Alternatively, it has been reported that patients with emphysema have elevated plasma levels of tumor necrosis factor-α and reactive oxygen species [54], which decrease the availability of nitric oxide (NO), an important vasodilator in muscle. However, whilst Berry et al. [55] and Kerley et al. [56] proposed that dietary nitrate supplementation might be beneficial, it has recently been demonstrated that this is ineffective in people with COPD [57].

The notion of an intramyocyte limitation is supported by the present study in which we observed a slower [HbO2] response in patients with emphysema compared to published values for healthy older adults [8–15 s;43, 45]. It is known that patients with COPD have a lower muscle oxidative capacity due to a decreased oxidative enzyme activity, reduced mitochondrial density and increased proportion of type II muscle fibers [58]. The latter have a lower oxidative but a higher glycolytic capacity and (at least in mouse muscle) an inherently slower VO2 response relative to type I muscle fibers [59, 60]. Therefore, it could be speculated that a greater reliance on type II muscle fibers in patients with emphysema during heavy intensity exercise explains our observed slowing of the dynamic VO2 response. Further evidence to support this notion was provided by Casaburi et al. [5] who reported a significantly faster VO2 response in patients with COPD following exercise training despite no change in HR kinetics. Whilst the present study was not designed to investigate the mechanistic basis of the slower VO2 kinetics in people with pulmonary disease, it seems likely to involve impairments in both oxygen delivery and myocyte function.

Dyspnea is the most common and debilitating symptom in patients with IPF in whom it is the primary impairment to quality of life [61]. It is therefore surprising that there is such a paucity of information regarding the physiological response to heavy exercise in IPF and whether the aforementioned mechanisms relating to emphysema also apply to this condition. Our findings relating to VO2 recovery suggest that patients with emphysema and IPF exhibit similar overall functional impairment, although modulatory factors may differ in the two conditions. Specifically, our patients with emphysema demonstrated an approximately 27% slower HR response than those with IPF and this might indicate a greater relative impairment of oxygen delivery in these patients although our small sample size dictates this difference should be interpreted with caution.

Contrary to expectation and the findings of Chiappa et al. [4], a negligible O2 slow component was observed in both patient groups. Whilst this could be due to methodological limitations related to measurement of relative exercise intensity in our patients, it is pertinent to note the exercise until volitional exhaustion in the study of Chiappa et al. [4]. Given recent advances in our understanding of the etiology of the slow component [62, 63], further work is warranted to ascertain the applicability of such findings to patients with lung disease.
Whilst we believe the present study extends our understanding of the exercise intolerance characteristic of IPF patients and provides an insight into a clearly defined emphysema patient group, it has certain limitations. Specifically, [HHb] data was not collected in the healthy control participants, arterial desaturation was not measured and the population sizes were relatively small; all these factors could potentially influence the conclusions we have drawn. Indeed, it is important that our results are considered with caution given the lower statistical power associated with the small sample size. A greater sample size may also allow questions with regard to the optimal modeling strategy for [HHb] data to be investigated, with concerns raised that the present method may not optimally describe the initial transient response. Moreover, the low response amplitude and subsequent signal-to-noise ratio requires caution in the interpretation of the present findings, especially with regards to potential discrepancies in relative exercise intensity which may have influenced the presence of a $V\cdot O_2$ slow component. It is also pertinent to note the age of the current participants; underlying age-related declines in the dynamic exercise response limit the attribution of the observed impairments to solely COPD. Furthermore, the present study used heart rate kinetics as a proxy for oxygen delivery and we did not formally assess dyspnea during exercise. Finally, to limit the burden on our patients who had relatively severe lung disease, a supra-maximal validation bout for peak $V\cdot O_2$ was not performed. Despite these limitations, we believe this pilot study provides important information, which could inform future research into functional limitations of people with IPF and emphysema.

Conclusions
In conclusion, the pathological conditions of emphysema and IPF both impair the normal dynamic respiratory and cardiac responses following the onset of exercise. Specifically, they are characterised by significantly slower $V\cdot O_2$, HR and [HHb] kinetics relative to healthy controls, suggesting that both oxygen delivery and metabolic inertia limit the O2 response in these patients. Our findings may help in the development of future therapeutic strategies designed to improve functional aerobic fitness in people suffering from emphysema and IPF. Specifically, regimes that target enhanced systemic O2 delivery and peripheral muscle O2 availability may be particularly effective.

Abbreviations
$V\cdot O_2$: Rate of oxygen uptake; [HHb]: Deoxyhemoglobin; Amp: Amplitude; BF: Body fat; COPD: Chronic obstructive pulmonary disease; DLco: Carbon monoxide transfer coefficient; FEV1: Forced expiratory volume in one second; FVC: Forced vital capacity; GET: Gas exchange threshold; HR: Heart rate; IPF: Idiopathic pulmonary fibrosis; Kco: Carbon monoxide transfer factor; MRT: Mean response time; NIRS: Near infrared spectroscopy; NO: Nitric oxide; O2: Oxygen; TD: Time delay; VCO2: Rate of carbon dioxide production; VE: Minute ventilation; VT: Tidal volume; τ: Time constant

Acknowledgements
The authors would like to thank the nurses and managers at the Clinical Research Unit at Swansea University for their assistance in collecting the data for this study.

Funding
No funding was received for this study.

Availability of data and material
The datasets used in the current study are available from the corresponding author on reasonable request.

Authors’ contributions
MAM was responsible for the conception, design, implementation, analysis and write up of the study. MJL was responsible for the conception, implementation and write up of the study. TW and NC were responsible for the implementation of the study. M.J.L was responsible for the conception and write up of the study. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study protocol and patient information sheets and consent forms were approved by the National Research Ethics Service Committee – South West Wales (REC reference 12/WA/0244) and the local Research and Development (R&D) office.

Author details
1A-STEM, College of Engineering, Swansea University, Swansea, UK. 2College of Medicine, Swansea University, Swansea, UK. 3Respiratory Unit, Morriston Hospital, Swansea, UK.

Received: 12 June 2016 Accepted: 10 January 2017
Published online: 31 January 2017

References
1. Whipp BJ, Ward SA. Physiological determinants of pulmonary gas-exchange kinetics during exercise. Med Sci Sport Exerc. 1990;22(1):62–71.
2. Somfay A, Pérezszád J, Lee S-M, Casaburi R. Effect of hyperoxia on gas exchange and lactate kinetics following exercise onset in nonhypoxemic copd patients. Chest. 2002;121(2):393–400.
3. Puente-Maestu L, Sanch M, Sanch P, Ruiz de Ona J, Rodriguez-Hermosa J, Whipp B. Effects of two types of training on pulmonary and cardiac responses to moderate exercise in patients with COPD. Eur Respir J. 2000;15(6):1026–32.
4. Chiappa GL, Borghi-Silva A, Ferreira LF, Carascosa C, Oliveira CC, Maa J, et al. Kinetics of muscle deoxygenation are accelerated at the onset of heavy-intensity exercise in patients with COPD: relationship to central cardiovascular dynamics. J Appl Physiol. 2008;104(5):1341–50.
5. Casaburi R, Ponzias J, Buys MR, Canthers ER, Chang RS, Cooper GB. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1997;155(3):1541–51.
6. Aliverti A, Macdern PT. How and why exercise is impaired in COPD. Respiration. 2001;68(3):229–39.
7. American Thoracic Society and European Respiratory Society: Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(1):S40.
8. Maltais F, Jobin J, Sullivan MJ, Bernard S, Whittom F, Killian KJ, et al. Metabolic and hemodynamic responses of lower limb during exercise in patients with COPD. J Appl Physiol. 2004;96(5):1899–96.
9. Richardson RS, Leek BT, Gavin TP, Haseler LJ, Mudallar SRD, Henry R, et al. Reduced mechanical efficiency in chronic obstructive pulmonary disease but normal peak Vo2 with small muscle mass exercise. Am J Respir Crit Care Med. 2004;169(1):89–96.
10. Sára E, Rosa J, Marrades RM, Alonso J, González de Suizo JM, Moreno A, et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(6):1726–34.
11. Whittom F, Jobin J, Simard P-M, Leblanc P, Simard C, Bernard S, et al. Histochemical and morphological characteristics of the vastus lateralis
muscle in patients with chronic obstructive pulmonary disease. Med Sci Sport Exer. 1998;30(10):1467–74.

12. Simard C, Maltais F, LeBlanc P, Simard M, Jobin J. Mitochondrial and capillary changes in vastus lateralis muscle of COPD patients: electron microscopy study. Med Sci Sport Exer. 1996;28:595.

13. Maltais F, Simard AA, Simard C, Jobin J, Desgagnés P, LeBlanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med. 1996;153(1):288–93.

14. Evans AB, Al-Harym AJ, Hrovat MI, Pappagianopoulos P, Wain JC, Ginnis LC, et al. Abnormal skeletal muscle oxidative capacity after lung transplantation by 31P-NMR. Am J Respir Crit Care Med. 1997;155(2):151–21.

15. Palange P, Galassetti P, Mannix ET, Farber MO, Manfredi F, Serra P, et al. Oxygen effect on O2 deficit and VO2 kinetics during exercise in obstructive pulmonary disease. J Appl Physiol. 1995;78(6):2228–34.

16. Nery LE, Wasserman K, Andrews JD, Huntsmen DJ, Hansen JE, Whipp BJ. Ventilatory and Gas exchange during exercise in chronic airways obstruction. J Appl Physiol. 1986;43:594–602.

17. Lamara N, Whipp BJ, Ward SA, Wasserman K. Effect of interbreath fluctuations on characterising exercise gas exchange kinetics. J Appl Physiol. 1987;63:2003–12.

18. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol-Med. 2009;4(1):345–59.

19. LoRusso TJ, Belman MJ, Elshoff JD, Koerner SK. Prediction of maximal exercise capacity in obstructive and restrictive pulmonary disease. Chest. 1993;104(6):1748–54.

20. Visscher DW, Myers JL. Bronchiolitis. Proc Am Thorac Soc. 2006;3(1):41–5.

21. Gribbin J, Hubbard RB, Le Jeune I, Smith CJP, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 1997;52(1):15–9.

22. Visscher DW, Myers JL. Bronchiolitis. Proc Am Thorac Soc. 2006;3(1):41–5.

23. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic parameters of VO2 heart rate and muscle deoxygenation kinetics affected by serial moderate-intensity exercise transitions in a single day? Eur J Appl Physiol. 2011;111(4):591–600.

24. Spencer MD, Murias JM, Lamb HP, Kowalchuk JM, Paterson DH. Are the parameters of VO2 heart rate and muscle deoxygenation kinetics affected by serial moderate-intensity exercise transitions in a single day? Eur J Appl Physiol. 2011;111(4):591–600.

25. Spencer MD, Murias JM, Kowalchuk JM, Paterson DH. Effect of moderate-intensity work rate increase on phase II tVO2, functional gain and Δ[Hb]. Eur J Appl Physiol. 2013;113(3):545–57.

26. Murias JM, Spencer M, Kowalchuk J, Paterson D. Muscle deoxygenation to O2 uptake kinetics and muscle deoxygenation during moderate-intensity exercise in children. Sports Med. 2002;33(9):651–69.

27. Francesconi MP, Cetotto V, Bellori R. Confidence intervals for the parameters estimated from simulated O2 uptake kinetics effects of different data treatments. Exp Physiol. 2014;99(1):187–95.

28. Keir DA, Murias JM, Paterson DH, Kowalchuk JM. Breath-by-breath pulmonary O2 uptake kinetics: effect of data processing on confidence in estimating model parameters. Exp Physiol. 2014;99(1):1511–22.

29. MacPhee SL, Shoemaker JK, Paterson DH, Kowalchuk JM. Kinetics of O2 uptake, leg blood flow, and muscle deoxygenation are slowed in the upper compared with lower region of the moderate-intensity exercise domain. J Appl Physiol. 2005;99(5):1822–34.

30. Grey TM, Spencer MD, Belfry GR, Kowalchuk JM, Paterson DH, Murias JM. Effects of Age and long-term endurance training on VO2 kinetics. Med Sci Sport Exerc. 2015;47(2):289–98.

31. Marwood S, Roche D, Rowland TW, Garrard M, Unnithan V. Faster pulmonary O2 uptake kinetics and muscle deoxygenation during moderate-intensity exercise in children. Sports Med. 2002;33(9):651–69.

32. Bailey SJ, Winyard PG, Vanhatalo A, Blackwell JR, DiMenna FJ, Wilkerson DP, et al. Influence of repeated sprint training on pulmonary O2 uptake kinetics and muscle deoxygenation during moderate-intensity exercise. J Appl Physiol. 2004;97(1):165–72.

33. Visscher DW, Myers JL. Bronchiolitis. Proc Am Thorac Soc. 2006;3(1):41–5.

34. Murias JM, Spencer M, Kowalchuk J, Paterson D. Muscle deoxygenation to O2 uptake kinetics and muscle deoxygenation during moderate-intensity exercise. J Appl Physiol. 2004;97(1):165–72.

35. Heindl S, Lehment M, CriÉE C-P, Hansefuss G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164(4):597–601.

36. Alveri A, Allevrò S, Nellàcà RL, Lo Mauro A, Pedotti A, Calverly PMA. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax. 2004;59(3):210–6.

37. Vogiatzis I, Georgiadou O, Golemati S, Alveri A, Kosmas E, Kastanis E, et al. Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease. Thorax. 2005;60(6):723–9.

38. Warner HR, Cox A. A mathematical model of heart rate control by sympathetic and vagus efferent influence. J Appl Physiol. 1962;17(2):349–55.

39. Vogiatzis I, Zakyntinos H, Georgiadou O, Golemati S, Pedotti A, Macklem PT, et al. Oxygen kinetics and delay during recovery from esophageal flow-limited exercise in healthy humans. Eur J Appl Physiol. 2007;99(3):265–74.

40. Harms CA, Wetter TJ, McClaran SR, Pegelow DF, Nicolle GA, Nelson WB, et al. Effects of respiratory muscle work on cardiac output and its distribution during maximal exercise. J Appl Physiol. 1998;85(6):2609–18.

41. Tschakovsky ME, Huggson RL. Rapid blunting of sympathetic vasoconstriction in the human forearm at the onset of exercise. J Appl Physiol. 2003;94(5):1775–82.

42. Gan WQ, Man FP, Senthivelan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.

43. Berry MJ, Justus NW, Hauser JJ, Case AH, Helms CC, Basu S, et al. Dietary nitrate supplementation improves exercise performance and decreases blood pressure in COPD patients. Nitric Oxide. 2015;48:22–30.

44. Kerley CP, Cahill K, Bolger K, McGowan A, Burke C, Faul J, et al. Dietary nitrate supplementation on the oxygen cost of cycling, walking performance and resting blood pressure in individuals with chronic obstructive pulmonary disease: A double blind placebo controlled, randomised control trial. Nitric Oxide. 2015;30(1):187–85.

45. Kim HC, Mofarrah M, Hussain SNA. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(4):637–58.
59. Crow MT, Kushmerick MJ. Chemical energetics of slow-twitch and fast-twitch muscles of the mouse. J Gen Physiol. 1982;79(1):147–66.
60. Krstrup P, Secher NH, Relu MU, Hellsten Y, Soderlund K, Bangsbo J. Neuromuscular blockade of slow twitch muscle fibres elevates muscle oxygen uptake and energy turnover during submaximal exercise in humans. J Physiol. 2006;586(24):6037–48.
61. Swigris JJ, Steiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):181–8.
62. Zoladz JA, Majerczak J, Grassi B, Szukutnik Z, Korostyński M, Golda S, et al. Mechanisms of Attenuation of Pulmonary VO2 Slow Component in Humans after Prolonged Endurance Training. PLoS One. 2016;11(4):e0154135.
63. Jones AM, Grassi B, Christensen PM, Krstrup P, Bangsbo J, Poole DC. The slow component of VO2 kinetics: mechanistic bases and practical applications. Med Sci Sport Exerc. 2011;43(1):2046–62.
64. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6 Suppl 16:15–40.
65. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault J-C. Standardization of the measurement of transfer factor (diffusing capacity). Eur Respir J. 1993;6 Suppl 16:41–52.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit